Amylyx Pharmaceuticals, Inc.
AMLX
Revenue
-1.02M
▼-89.67M▼-101.15%
3 Months ChangeAssets
332.16M
▼-85.30M▼-20.43%
3 Months ChangeLiabilities
70.85M
▼-22.17M▼-23.83%
3 Months ChangeFree Cash Flow
-556.00k
▲4.77M▲89.55%
12 Months ChangeRevenue/Cost Of Revenue
Revenue
Cost Of Revenue
Loading...
| Date | Revenue | Cost Of Revenue |
|---|---|---|
Net Profit/Loss
Net Profit/Loss
Baseline
Loading...
| Date | Net Profit/Loss |
|---|---|
Assets/Liabilities
Assets
Liabilities
Loading...
| Date | Assets | Liabilities |
|---|---|---|
Cash Flows
Operating (Cash Flow)
Investing (Cash Flow)
Financing (Cash Flow)
Free Cash Flow
Loading...
| Date | Operating (Cash Flow) | Investing (Cash Flow) | Financing (Cash Flow) | Free Cash Flow |
|---|---|---|---|---|
EPS
EPS (Diluted)
Loading...
| Date | EPS | EPS (Diluted) |
|---|---|---|
Outstanding Shares
Loading...
| Date | Outstanding Shares |
|---|---|
Recent 8-K/10-Q Filings
2024-10-17
Form 8-K
ID: 0001193125-24-238572
2024-08-08
Form 10-Q
ID: 0000950170-24-093311
2024-08-08
Form 8-K
ID: 0000950170-24-093304
2024-07-10
Form 8-K
ID: 0001193125-24-177000
2024-06-21
Form 8-K
ID: 0000950170-24-076339
2024-06-06
Form 8-K
ID: 0001193125-24-156050
2024-05-09
Form 10-Q
ID: 0000950170-24-056269
2024-05-09
Form 8-K
ID: 0000950170-24-056254
2024-04-10
Form 8-K
ID: 0001193125-24-091463
2024-04-04
Form 8-K
ID: 0001193125-24-086609